According to DataM Intelligence "the Oncology Therapy  market size reached US$ 193.98 billion in 2024 and is projected to reach US$ 440.26 billion by 2033, expanding at a robust CAGR of 9.6% from 2025 to 2033."This growth underscores the critical need for effective, targeted, and innovative oncology treatments that improve patient outcomes and quality of life.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/oncology-therapy-market?pratik 

United States: Recent Industry Developments

✅ In September 2025, Bristol Myers Squibb launched a next-generation immuno-oncology therapy targeting multiple solid tumors, designed to enhance T-cell activation and improve long-term survival outcomes.

✅ In August 2025, Merck expanded clinical trials for combination checkpoint inhibitor therapies in advanced-stage cancers, aiming to boost efficacy and reduce immune-related adverse events.

✅ In July 2025, Amgen introduced a bispecific antibody therapy for hematologic malignancies, supporting precision-targeted treatment and improved patient response rates.

✅ In June 2025, Gilead Sciences invested in CAR-T cell therapy research for solid and blood cancers, advancing personalized treatment options and accelerating clinical translation.

Japan: Recent Industry Developments

✅ In September 2025, Takeda Pharmaceutical launched novel immuno-oncology therapies for Japanese patients with advanced solid tumors, enhancing immune-mediated tumor suppression and survival outcomes.

✅ In August 2025, Chugai Pharmaceutical expanded clinical studies on combination therapies integrating checkpoint inhibitors and targeted agents for improved oncology care.

✅ In July 2025, Daiichi Sankyo introduced bispecific antibody therapies for hematologic cancers with optimized safety and efficacy tailored for local patient populations.

✅ In June 2025, Astellas Pharma invested in next-generation cellular and gene-based oncology therapies, strengthening Japan's precision medicine pipeline and clinical research capabilities.

Market Drivers and Restraints

The primary driver of market growth is the rising global incidence of cancer. As per the National Institutes of Health (NIH), in 2022, there were nearly 20 million new cancer cases worldwide, with approximately 9.7 million cancer-related deaths. Projections indicate that by 2030, annual cancer cases will reach 24.1 million, escalating demand for advanced oncology therapies. Breast cancer, in particular, remains a leading concern, with an expected 2.7 million new cases by 2030, up from 2.3 million in 2022.

Despite these opportunities, adverse effects associated with cancer therapies present challenges. Chemotherapy can harm healthy cells, leading to toxicity, while immunotherapies may trigger immune-related side effects. Targeted therapies, although precise, may still cause molecular-specific adverse events, sometimes limiting treatment adoption.

Segmentation Analysis: Therapy, Application, and End-User

The oncology therapy market is comprehensively segmented by therapy type, application, and end-user, providing insights into treatment adoption patterns and market potential.

By Therapy

In 2024, chemotherapy retained a significant share due to its established clinical efficacy and widespread availability. Targeted therapies gained traction, offering precision treatment with fewer off-target effects. Immunotherapy emerged as a revolutionary option for cancers such as melanoma and lung cancer, driving significant research investments. Hormonal therapy continues to be pivotal for hormone-driven cancers like breast and prostate cancer, while radiation therapy remains essential for localized tumor control. The "others" category

By Application

Among cancer types, breast cancer dominates the oncology therapy market, fueled by increasing prevalence and advancements like Trastuzumab deruxtecan, launched in January 2024 by AstraZeneca India Pharma Ltd. in collaboration with Daiichi Sankyo. Other major applications include lung cancer, blood cancer, prostate cancer, colorectal cancer, stomach cancer, liver cancer, esophageal cancer, cervical cancer, ovarian cancer, bladder cancer, head and neck cancer, skin cancer (melanoma), pancreatic cancer, and kidney cancer. Collectively, these cancers drive demand for both traditional and innovative therapies.

By End-User

Hospitals serve as the primary end-user, offering comprehensive oncology care with multidisciplinary teams. Cancer research centers contribute by facilitating clinical trials and innovative therapy development. Specialty clinics, often focusing on targeted and immunotherapy interventions, complement hospital services. Other end-users include outpatient centers and home-based oncology care services, reflecting growing trends in patient convenience and personalized care.

Regional Analysis: USA and Japan

United States

North America holds a dominant market share, with the U.S. oncology therapy market valued at US$ 75.64 billion in 2023, driven by an aging population, lifestyle-related cancer risks, and advanced healthcare infrastructure. Recent developments include FDA approval of CARVYKTI (ciltacabtagene autoleucel) by Johnson & Johnson in April

2024 for relapsed or refractory multiple myeloma, highlighting the country's rapid adoption of innovative CAR-T cell therapies. The U.S. market is characterized by frequent mergers, acquisitions, and collaborations, fostering faster market expansion.

Japan

Japan represents a significant Asia-Pacific oncology market, underpinned by government-led cancer initiatives and robust clinical research ecosystems. Recent approvals include novel targeted therapies and immunotherapies for breast and hematological cancers, aligning with the nation's aging population and high cancer prevalence. Strategic partnerships between Japanese biotech firms and global pharma players are accelerating access to next-generation oncology therapies.

Competitive Landscape: Top Players

The oncology therapy market is highly competitive, with major players driving innovation through R&D, strategic collaborations, and product launches.

1. Amgen Inc.

Amgen focuses on biologics and targeted therapies, enhancing patient survival through precision oncology solutions. Recent expansions include novel monoclonal antibodies targeting hematological cancers.

2. AstraZeneca

AstraZeneca is renowned for targeted therapies and immuno-oncology innovations, exemplified by its Trastuzumab deruxtecan launch. Strategic partnerships strengthen its global oncology pipeline.

3. Bayer AG

Bayer integrates chemotherapy and targeted therapies, leveraging R&D in hematology and solid tumors. Its oncology strategy emphasizes combination therapies and global clinical trials.

4. Merck & Co., Inc.

Merck drives growth via immune checkpoint inhibitors and combination immunotherapies, particularly for lung, melanoma, and kidney cancers. Continuous pipeline expansion ensures market leadership.

5. Johnson & Johnson Services, Inc.

Johnson & Johnson leads in CAR-T cell therapies and personalized oncology solutions, highlighted by recent FDA approvals. Their approach combines innovation with strong clinical and regulatory expertise.

Other notable players include F. Hoffmann-La Roche Ltd, Novartis AG, GSK plc, Eli Lilly and Company, and Rigel Pharmaceuticals, Inc., all contributing to market growth through advanced research, novel product launches, and global outreach.

Future Outlook

The Global Oncology Therapy Market is poised for continued expansion, fueled by rising cancer prevalence, personalized medicine, and technological innovation. The market's growth trajectory signals opportunities for stakeholders across pharmaceutical companies, research institutions, healthcare providers, and investors. By 2033, oncology therapy is expected to redefine cancer care, offering more effective, targeted, and patient-friendly treatments, while advancing the global mission to reduce cancer morbidity and mortality.

✅ Competitive Landscape

✅ Technology Roadmap Analysis

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Consumer Behavior & Demand Analysis

✅ Import-Export Data Monitoring

✅ Live Market & Pricing Trends

Contact Us -

Company Name: DataM Intelligence

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.